(Q51821033)

English

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

scientific article published on 19 June 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

phase III clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

David Cunningham

11

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Victoria E Shaw

28

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

John P Neoptolemos

33

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

object named as

Tamas Hickish

22

0 references

object named as

Trevor Cox

3

0 references

Eithne Costello

object named as

Eithne Costello

29

0 references

Srinivasan Madhusudan

object named as

Srinivasan Madhusudan

9

0 references

Dean J Naisbitt

object named as

Dean Naisbitt

30

1 reference

ORCID Public Data File 2021

William Greenhalf

27

object named as

William Greenhalf

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

1

object named as

Gary Middleton

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Jonathan Wadsley

5

object named as

Jonathan Wadsley

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

6

object named as

David Propper

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

12

object named as

Stephen Falk

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

7

object named as

Fareeda Coxon

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

13

object named as

Nick Wadd

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

15

object named as

Pippa Corrie

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Charlotte L Rawcliffe

31

object named as

Charlotte Rawcliffe

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

26

object named as

Alan Anthoney

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

19

object named as

Martin Eatock

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

author name string

Paul Silcocks

2

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Paul Ross

8

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Tom Roques

10

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Mark Harrison

14

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Tim Iveson

16

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Angus Robinson

17

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Karen McAdam

18

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Jeff Evans

20

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Caroline Archer

21

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Angel Garcia-Alonso

23

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Marianne Nicolson

24

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

William Steward

25

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Gemma Nanson

32

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

publication date

19 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

15

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

8

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

829-840

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic cancer vaccines: current status and moving forward

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of telomeres in stem cells and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telomerase and the search for the end of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-Analyses of Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Understanding metastasis in pancreatic cancer: a call for new clinical approaches

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel anticancer therapeutics targeting telomerase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

No end in sight for telomerase-targeted cancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970236-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70236-0

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 April 2018

http://europepmc.org/abstract/MED/24954781

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51821033&oldid=1856526785"